Sarepta Therapeutics (NASDAQ:SRPT) Raised to Hold at Deutsche Bank Aktiengesellschaft

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by research analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, FinViz reports. The brokerage currently has a $18.00 price objective on the biotechnology company’s stock, up from their prior price objective of $14.00. Deutsche Bank Aktiengesellschaft‘s price target would indicate a potential upside of 4.41% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Weiss Ratings lowered Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 28th. William Blair raised Sarepta Therapeutics to a “hold” rating in a research report on Wednesday, September 23rd. Zacks Research downgraded Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Royal Bank Of Canada raised their price target on shares of Sarepta Therapeutics from $17.00 to $18.00 and gave the stock a “sector perform” rating in a research note on Friday. Finally, HC Wainwright reiterated a “sell” rating and issued a $5.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 5th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and six have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $23.67.

Sarepta Therapeutics Trading Down 3.3%

SRPT opened at $17.24 on Tuesday. The stock has a market capitalization of $1.82 billion, a P/E ratio of -12.58, a P/E/G ratio of 0.35 and a beta of 0.45. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics has a 12 month low of $14.68 and a 12 month high of $24.68. The firm’s fifty day simple moving average is $19.06 and its 200 day simple moving average is $18.62.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.05. The firm had revenue of $381.35 million for the quarter, compared to the consensus estimate of $352.20 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%. The company’s revenue for the quarter was down 4.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.13) EPS. As a group, research analysts anticipate that Sarepta Therapeutics will post 3.27 EPS for the current fiscal year.

Institutional Trading of Sarepta Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in Sarepta Therapeutics in the second quarter valued at approximately $341,339,000. First Trust Advisors LP grew its stake in shares of Sarepta Therapeutics by 107.6% in the first quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock valued at $89,995,000 after buying an additional 2,143,211 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Sarepta Therapeutics by 26.6% in the first quarter. Bank of America Corp DE now owns 2,145,926 shares of the biotechnology company’s stock valued at $46,695,000 after buying an additional 450,336 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Sarepta Therapeutics by 43.6% in the first quarter. Renaissance Technologies LLC now owns 1,665,078 shares of the biotechnology company’s stock valued at $36,232,000 after buying an additional 505,500 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Sarepta Therapeutics during the second quarter worth $17,494,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches.

The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.

Sarepta is headquartered in Cambridge, Massachusetts.